Mineralys Therapeutics Stock Quote MLYS - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

12.34

Bid

11.40

Ask

15.25

Volume

481,045

11.55 Day's Range 12.50

7.29 52 Week Range 16.905

Market Cap

614.145M

Previous Close

11.83

Open

11.83

Last Trade

339

12.34

(priorref)

Last Trade Time

Financial Volume

$ 5,800,430

VWAP

12.058

Average Volume (3m)

174,016

Shares Outstanding

49,768,669

Dividend Yield

PE Ratio

-8.54

Earnings Per Share (EPS)

-1.44

Revenue

Net Profit

-71.9M

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase in... Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.mineralystx.com

Headquarters

Wilmington, Delaware, USA

Founded

Mineralys Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MLYS. The last closing price for Mineralys Therapeutics was $11.83. Over the last year, Mineralys Therapeutics shares have traded in a share price range of $ 7.29 to $ 16.905.

Mineralys Therapeutics currently has 49,768,669 shares outstanding. The market capitalization of Mineralys Therapeutics is $588.76 million. Mineralys Therapeutics has a price to earnings ratio (PE ratio) of -8.54.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

– Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 – – Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate...

Mineralys Therapeutics to Participate in Upcoming Investor Conferences

RADNOR, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension...

Form 8-K - Current report

Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension

– Topline data now anticipated in mid first half of 2025 – – Management to host virtual KOL event today to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal...

Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024

RADNOR, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension...

Form 8-K - Current report

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.35	2.91909924937	11.99	12.57	11.19	101720	11.93297886	CS
4	0.35	2.91909924937	11.99	14.19	11.19	144011	12.78599062	CS
12	0.24	1.98347107438	12.1	15.25	11.19	174016	13.31232878	CS
26	0.59	5.02127659574	11.75	15.25	8.58	198077	12.56491444	CS
52	4.46	56.5989847716	7.88	16.905	7.29	175363	12.63800781	CS
156	-8.76	-41.5165876777	21.1	21.98	5.85	185588	12.89322856	CS
260	-8.76	-41.5165876777	21.1	21.98	5.85	185588	12.89322856	CS

MLYS - Frequently Asked Questions (FAQ)

What is the current Mineralys Therapeutics share price?

The current share price of Mineralys Therapeutics is $ 12.34

How many Mineralys Therapeutics shares are in issue?

Mineralys Therapeutics has 49,768,669 shares in issue

What is the market cap of Mineralys Therapeutics?

The market capitalisation of Mineralys Therapeutics is USD 588.76M

What is the 1 year trading range for Mineralys Therapeutics share price?

Mineralys Therapeutics has traded in the range of $ 7.29 to $ 16.905 during the past year

What is the PE ratio of Mineralys Therapeutics?

The price to earnings ratio of Mineralys Therapeutics is -8.54

What is the reporting currency for Mineralys Therapeutics?

Mineralys Therapeutics reports financial results in USD

What is the latest annual profit for Mineralys Therapeutics?

The latest annual profit of Mineralys Therapeutics is USD -71.9M

What is the registered address of Mineralys Therapeutics?

The registered address for Mineralys Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Mineralys Therapeutics website address?

The website address for Mineralys Therapeutics is www.mineralystx.com

Which industry sector does Mineralys Therapeutics operate in?

Mineralys Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
MYSZMy Size Inc	$ 4.2001 (211.12%)	121.03M
NVNINVNI Group Ltd	$ 8.26 (209.36%)	78.06M
TPICTPI Composites Inc	$ 2.45 (100.82%)	34M
ICGIntchains Group Ltd	$ 8.77 (88.60%)	527.94k
HSDTHelius Medical Technologies Inc	$ 0.884851 (84.34%)	121.95M
CYNCYNGN Inc	$ 0.4603 (-71.41%)	27.91M
MTEMMolecular Templates Inc	$ 0.1502 (-57.09%)	8.75M
PRFXPainReform Ltd	$ 5.15 (-53.85%)	2.94M
GALTGalectin Therapeutics Inc	$ 1.03 (-48.50%)	9.27M
BCABBioAtla Inc	$ 0.6923 (-41.82%)	6.25M
EDBLEdible Garden AG Inc	$ 0.24 (65.06%)	354.32M
APTOAptose Biosciences Inc	$ 0.28 (64.51%)	305.1M
TNXPTonix Pharmaceuticals Holding Corporation	$ 0.606999 (6.49%)	292.16M
NVDANVIDIA Corporation	$ 134.70 (3.08%)	287.21M
PLTRPalantir Technologies Inc	$ 80.55 (8.54%)	277.63M